- Home
- BIT vs URGN Comparison
BIT vs URGN Comparison
Compare BIT & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIT
- URGN
- Stock Information
- Founded
- BIT 2013
- URGN 2004
- Country
- BIT United States
- URGN United States
- Employees
- BIT N/A
- URGN N/A
- Industry
- BIT Trusts Except Educational Religious and Charitable
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- BIT Finance
- URGN Health Care
- Exchange
- BIT Nasdaq
- URGN Nasdaq
- Market Cap
- BIT 581.8M
- URGN 465.9M
- IPO Year
- BIT N/A
- URGN 2017
- Fundamental
- Price
- BIT $13.73
- URGN $9.67
- Analyst Decision
- BIT
- URGN Strong Buy
- Analyst Count
- BIT 0
- URGN 7
- Target Price
- BIT N/A
- URGN $37.21
- AVG Volume (30 Days)
- BIT 92.4K
- URGN 499.1K
- Earning Date
- BIT 01-01-0001
- URGN 05-12-2025
- Dividend Yield
- BIT 9.36%
- URGN N/A
- EPS Growth
- BIT N/A
- URGN N/A
- EPS
- BIT N/A
- URGN N/A
- Revenue
- BIT N/A
- URGN $90,398,000.00
- Revenue This Year
- BIT N/A
- URGN $38.65
- Revenue Next Year
- BIT N/A
- URGN $118.69
- P/E Ratio
- BIT N/A
- URGN N/A
- Revenue Growth
- BIT N/A
- URGN 9.29
- 52 Week Low
- BIT $13.65
- URGN $8.94
- 52 Week High
- BIT $15.97
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- BIT 41.45
- URGN 41.45
- Support Level
- BIT $13.27
- URGN $8.94
- Resistance Level
- BIT $13.79
- URGN $10.83
- Average True Range (ATR)
- BIT 0.37
- URGN 0.79
- MACD
- BIT -0.00
- URGN -0.07
- Stochastic Oscillator
- BIT 61.50
- URGN 29.67
About BIT BlackRock Multi-Sector Income Trust of Beneficial Interest
BlackRock Multi-Sector Income Trust is a closed-end investment management company. It invests on behalf of its clients. The fund's primary investment objective is to provide a high level of current income, with a secondary objective of capital appreciation. The company seeks to achieve its investment objectives by investing, under normal market conditions, a majority of its assets in loan and debt instruments and other investments with similar economic characteristics. Its portfolio consists of Corporate Bonds, Asset-Backed Securities, Preferred Securities, and others.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.